托法替布治疗难治性皮肌炎的开放标签初步研究
这项为期12周的开放标签研究评估了托法替布(JAK抑制剂)在10例难治性活动性皮肌炎患者中的疗效与安全性,所有患者每日接受11 mg缓释剂型。主要终点为基于国际肌炎评估与临床研究组改善定义的疾病活动改善,12周时全部10例均达到主要终点;根据2016年ACR/EULAR肌炎反应标准,5例(50%)为中度改善,另5例为轻度改善。CDASI活动度评分平均变化具有统计学显著性(基线28±15.4 vs 12周9.5±8.5,P=0.0005)。
要点
- 12周时全部10例难治性皮肌炎患者均达到主要疗效终点。
- 5例(50%)为中度改善,5例(50%)为轻度改善(2016 ACR/EULAR标准)。
- CDASI活动度评分平均变化显著(P=0.0005)。
核心结论
- 托法替布作为泛JAK抑制剂在难治性皮肌炎中显示出较强的临床疗效,未来应考虑开展JAK抑制剂的随机对照试验。
研究设计与样本
- 开放标签12周研究,纳入10例难治性活动性皮肌炎患者,每日给予托法替布缓释剂11 mg,治疗前完全洗脱所有保类固醇药物。
主要发现
- 12周时主要终点在全部10例受试者中达成,5例(50%)为中度改善,另5例为轻度改善(2016 ACR/EULAR肌炎反应标准)。
- CDASI活动度评分12周平均变化具有统计学显著性(基线28±15.4 vs 12周9.5±8.5,P=0.0005)。
- 血清趋化因子CXCL9/CXCL10水平较基线有统计学显著变化。
- 9例皮肤活检样本中3例显示STAT1信号显著下降并伴干扰素靶基因表达抑制。
- 10例受试者基线肌酸激酶平均±SD为82±34.8 IU/L,提示疾病活动主要位于皮肤。
关键数值与推荐
- 主要终点为基于国际肌炎评估与临床研究组改善定义的疾病活动改善。
- 反应率按2016年ACR/EULAR肌炎反应标准的总改善评分衡量。
- CDASI活动度评分基线28±15.4,12周9.5±8.5,P=0.0005。
- 基线肌酸激酶平均±SD为82±34.8 IU/L。
临床怎么用
- 对于难治性活动性皮肌炎,尤其是以皮肤病变为主且肌酸激酶不高的患者,托法替布可能作为治疗选择。
- 治疗前需完全洗脱保类固醇药物,并密切监测CDASI评分及血清趋化因子水平。
局限性
- 开放标签设计,样本量仅10例,缺乏对照组。
- 研究周期仅12周,长期疗效与安全性未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This open-label 12-week study was conducted to evaluate the efficacy and safety of tofacitinib, a JAK inhibitor, in treatment-refractory active dermatomyositis (DM). METHODS: Tofacitinib in extended-release doses of 11 mg was administered daily to 10 subjects with DM. Prior to treatment, a complete washout of all steroid-sparing agents was performed. The primary outcome measure was assessment of disease activity improvement based on the International Myositis Assessment and Clinical Studies group definition of improvement. Response rate was measured as the total improvement score according to the 2016 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) myositis response criteria. Secondary outcome measures included Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) scores, chemokine levels, immunohistochemical analysis of STAT1 expression in the skin, RNA sequencing analysis, and safety. RESULTS: At 12 weeks, the primary outcome was met in all 10 subjects. Five (50%) of 10 subjects experienced moderate improvement in disease activity, and the other 50% experienced minimal improvement according to the 2016 ACR/EULAR myositis response criteria. The secondary outcome of the mean change in the CDASI activity score over 12 weeks was statistically significant (mean ± SD 28 ± 15.4 at baseline versus 9.5 ± 8.5 at 12 weeks) (P = 0.0005). Serum chemokine levels of CXCL9/CXCL10 showed a statistically significant change from baseline. A marked decrease in STAT1 signaling in association with suppression of interferon target gene expression was demonstrated in 3 of 9 skin biopsy samples from subjects with dermatomyositis. The mean ± SD level of creatine kinase in the 10 subjects at baseline was 82 ± 34.8 IU/liter, highlighting that disease activity was predominantly located in the skin. CONCLUSION: This is the first prospective, open-label clinical trial of tofacitinib in DM that demonstrates strong clinical efficacy of a pan-JAK inhibitor, as measured by validated myositis response criteria. Future randomized controlled trials using JAK inhibitors should be considered for treating DM.
引用
- Paik JJ, Casciola-Rosen L, Shin JY, et al. Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients. Arthritis Rheumatol. 2021. PMID: 33258553. doi:10.1002/art.41602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。